Industries
Insurance
Directors & Officers Liability Insurance
Health Care Coverage
Mass Torts

Practices
Antitrust
Appellate
Commercial Litigation
Copyright, Trademark & Intellectual Property
Employment
Trade Secrets and Unfair Competition

Education
J.D.  Harvard Law School 1982, magna cum laude
B.A.  Oberlin College 1979, with high honors in government; Phi Beta Kappa

Awards and Honors
2007 Lawyer of the Year, Compliance Reporter ARC Award
2007 “Lawdragon 3000” Leading Lawyer

Bar Admissions
District of Columbia

Court Admissions
U.S. District Court - District of Columbia
U.S. Court of Appeals - 3rd Circuit
U.S. Court of Appeals - 4th Circuit
U.S. Court of Appeals - 5th Circuit
U.S. Court of Appeals - 7th Circuit
U.S. Court of Appeals - 9th Circuit
U.S. Court of Appeals - District of Columbia Circuit
U.S. Court of International Trade
U.S. Supreme Court

Professional Affiliations
Member, ABA Antitrust Section Task Force on Brand-Generic Patent Settlement Legislation, 2007 - Present
American Bar Association Advisory Committee 2006 - Present
American Bar Association, Antitrust Section and Litigation Section

 
Merril  Hirsh,  Partner

Washington, DC
(202) 662-2032
(202) 662-2190


DOWNLOAD V-CARD

Merril Hirsh is a partner in Ross, Dixon & Bell, LLP’s Washington, DC office. He joined the firm in 1989.

Prior to joining the firm, Mr. Hirsh was a Trial Attorney in the Civil Division of the United States Department of Justice. There, he represented federal agencies and employees in courts across the country, primarily in cases challenging the validity of agency action and regulations and the constitutionality of Acts of Congress. Among other experience, Mr. Hirsh was the lead counsel representing the United States Department of Education in the eight-month school desegregation trial in Kansas City, Missouri, the lead counsel representing the Veterans Administration in a two-month trial challenging the constitutionality of an Act of Congress, and one of the primary counsel responsible for negotiating an innovative Title VII class action employment settlement that reorganized the personnel practices at a major military base.

Since coming to RDB, Mr. Hirsh has maintained an active litigation and insurance practice. Mr. Hirsh’s litigation at RDB includes significant and successful litigation on behalf of plaintiffs and defendants in antitrust, intellectual property, securities, corporate, discrimination, class action, and other cases. For example, he is one of the attorneys responsible for the False Claims Act litigation that in December 1999 resulted in a jury verdict finding that Koch Industries, Inc. submitted over 24,000 false claims on Government or Native American oil leases. He also was one of the attorneys who obtained an $85 million settlement on behalf of a class of resellers of long-distance service involving telephone rates. Mr. Hirsh has been part of the team representing Horizon Sports Technology and its principals in antitrust and False Claims Act litigation alleging price fixing for carbon fiber, and the team defending the USA Track & Field Association in an antitrust challenge to its standards for competition. He has represented the Financial Planning Association in its successful challenge before the United States Court of Appeals for the District of Columbia Circuit to the SEC’s “broker-dealer” rule. His insurance practice includes representing the interests of directors and officers liability insurers in scores of matters, including complex securities, takeover and intellectual property cases, and coverage litigation and the interests of general liability carriers in asbestos litigation, and the interests of managed care errors and omissions insurers in underlying RICO litigation. He has been the lead counsel representing the primary executive liability insurance carrier in connection with the Allegheny Health, Education & Research Foundation (AHERF) bankruptcy and district court litigation and one of the primary general liability carriers in the Combustion Engineering bankruptcy proceeding.

A speaker on a number of issues, Mr. Hirsh is a chapter editor of the ABA Section of Antitrust Law’s Proof of Conspiracy Under the Federal Antitrust Laws (in publication); author of “Are False Positives Really So Negative? A Response to Kevin McDonald,” Antitrust, Vol. 17 No. 3, at 83 (Summer 2003), and “Can An Insurer and An Insured Settle an Insurance Policy?,” 11 Mealey’s Litigation Report at 15 (Oct. 28, 1997); co-author with other RDB attorneys of the appendix “Background of the Illinois Brick Decision,” ABA’s Indirect Purchaser Litigation Handbook (Aug 8, 2007); co-author with other RDB attorneys of the Sherman Act Section 2 chapter of the ABA’s Antitrust and Telecommunications Practice Guide; co-author of “I Didn’t Say Orphan Often: The Benefits of a Bright-Line Rule Banning Brand to Generic Payments in Hatch-Waxman Patent Settlements,” ABA Antitrust Health Care Chronicle, Vol. 19, No. 2 (Summer 2005); author of “The Essential Facilities Doctrine: Keeping the Word ‘Epithet’ from Becoming One,” March 2003; co-author with other RDB attorneys of the article “In Re High Fructose Corn Syrup: A New Form of Chicago School Education,” FindLaw and (in summary) in Corporate Counsel Magazine (December 2002) and National Law Journal (December 2002); author of “Settlement Allocation Under Directors and Officers Liability Insurance: A Return to Basics,” Coverage, March/April 1995 at 20; and author of “Settlement Allocation Under Directors’ and Officers’ Liability Policies Takes Another Turn: The Nordstrom Decision,” Coverage, May/June 1995 at 1.


Publications
8/8/2007  “Background of the Illinois Brick Decision,” Appendix, ABA Section of Antitrust Law’s Indirect Purchaser Litigation Handbook
8/7/2007  Letter on Reverse Payment Settlements, ANTITRUST Summer 2007 Issue
Summer 2005  “I Didn’t Say Orphan Often: The Benefits of a Bright-Line Rule Banning Brand to Generic Payments in Hatch-Waxman Patent Settlements,” ABA Antitrust Health Care Chronicle, Vol. 19, No. 2 (Summer 2005)
7/1/2003  “Are False Positives Really So Negative? A Response to Kevin McDonald,” ANTITRUST, Vol. 17 No. 3, at 83 (Summer 2003)
3/21/2003  The Essential Facilities Doctrine: Keeping the Word “Epithet” from Becoming One
11/1/2002  “In Re High Fructose Corn Syrup: A New Form of Chicago School Education,” Findlaw.com
10/28/1997  “Can An Insurer and An Insured Settle an Insurance Policy?,” 11 Mealey’s Litigation Report at 15
ABA’s Antitrust and Telecommunications Practice Guide, Sherman Act Section 2 Chapter, Co-Author

In The News
9/12/2008  RDB and DC Appleseed Team Submit Report to DC Councilman on DC's Attorney General
5/28/2008  RDB and Its Co-Counsel Obtain Settlements Totaling $76.25 Million in False Claims Action
3/19/2008  Merril Hirsh Wins Compliance Reporter Lawyer of the Year Award, RDB Attorneys Recognized for Success in FPA Case
2/1/2008  Merril Hirsh Quoted In Registered Rep Article On SEC’s RAND Report
9/14/2007  Twelve RDB Attorneys Named Finalists in Lawdragon 500 Leading Lawyers in America
9/10/2007  Merril Hirsh Honored at Financial Planning Association’s National Conference
4/4/2007  Hirsh Quoted in Registered Rep Article on Annulment of SEC Broker-Dealer Rule
3/30/2007  DC Circuit Strikes Down SEC Broker-Dealer Rule
1/17/2007  Merril Hirsh Testifies Before the Senate Judiciary Committee on Paying off Generics to Prevent Competition with Brand Name Drugs
7/11/2006  Merril Hirsh Quoted in Corporate Board Member Magazine Article
6/5/2006  InvestmentNews Article Discusses Financial Planning Association Case
5/25/2006  RDB Files Reply Brief on Behalf of The Financial Planning Association in its Challenge to the Broker-Dealer Rule
5/11/2006  Briefing in Lawsuit Challenging the SEC’s Broker-Dealer Rule Nears an End
4/28/2005  FPA Files New Lawsuit Against SEC

Events
6/23/2008  “The FTC v. Cephalon case: What does it mean for future brand-generic patent settlements?” ABA Section of Antitrust Law
6/19/2008  “A Dickensian View of Pharmaceutical Antitrust: Bleak House or Great Expectations?” Generic Drug Summit, Institute for International Research
5/8/2008  “Overturning the SEC ‘Broker Dealer Rule’ - What to Expect Going Forward,” 2008 fi360 National Conference
4/24/2008  “Should We Allow Brand Companies to Pay Generics to End Patent Challenges: James J. Kirkpatrick Meet Shana Alexander,” Law Seminars International, Seminar on Pharmaceutical Antitrust
3/3/2008  February In-House Counsel Antitrust Update for the ABA Section of Antitrust Law
10/25-26/2007  “The SEC’s Regulation of Fee-Based Brokerage Accounts: A Case Study in Administrative Law,” ABA Administrative Law Conference
4/24/2007  A General Practitioner’s Guide: What to do if Your Client has an Antitrust or Intellectual Property Issue
1/17/2007  “Paying Off Generics to Prevent Competition with Brand Name Drugs: Should it be Prohibited?” The Senate Judiciary Committee
9/8/2006  Law Seminars International, Seminar on International Cartels
6/28/2006  ABA Antitrust Section, Corporate Counseling Committee, In-House Counsel Antitrust Update
6/20/2006  Antitrust: The Business Case
5/12/2005  ABA Antitrust Health Care Conference
4/1/2005  ABA Antitrust Spring Meeting

RDB Alerts
Antitrust
RDB Antitrust Alert, Editor, 2003-Present
D&O Liability
5/8/2008 Seventh Circuit Holds that Failure to Seek Consent to Settlement Bars Coverage
© 2008 Ross, Dixon & Bell, LLP . Washington . Orange County . San Diego . Chicago